NEW YORK (GenomeWeb News) – Rubicon Genomics today said that Velesco Pharmaceutical Services will manufacture its Transplex kits that it will supply for use with Agendia's breast cancer diagnostics.
Last week, Rubicon said that Agendia would use its whole-genome RNA amplification technology with Agendia's breast cancer diagnostic tests. Under the deal, Agendia will incorporate Rubicon's TransPlex technology into the analysis of formalin fixed, paraffin-embedded patient samples for use in testing with its Symphony suite of breast cancer diagnostics.
Rubicon noted today that cGMP production of the TransPLEX kits is required for FDA clearance of the tests.
"Velesco provides us an immediate pathway to cGMP kits for diagnostic use and it has the capacity to rapidly expand cGMP production as sales of our diagnostic kits ramp up," Rubicon CEO James Koziarz said in a statement. "We look forward to a mutually beneficial relationship as we grow our clinical diagnostics business."
Financial and other terms of the agreement were not disclosed.